Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01618968 · ClinicalTrials.gov registry record · Phase 2
Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device
A Phase 2 study of Rheumatoid Arthritis (RA), sponsored by Antares Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 49
- Enrollment target
- 1
- Study location
NCT01618968: Completed Phase 2 study of Rheumatoid Arthritis (RA), sponsored by Antares Pharma.
NCT01618968 is a Phase 2 study of Rheumatoid Arthritis (RA) that has completed, run by Antares Pharma. The registered enrollment target is 49 participants, below the 265-participant average among 17 other Rheumatoid Arthritis (RA) trials with a reported enrollment target (82% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01618968, a Phase 2 study of Rheumatoid Arthritis (RA), has completed, sponsored by Antares Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 49 participants
- Enrollment target
- 1
- Study location
Study Summary
Relative Bioavailability Comparison study
Primary Outcome
Dose-normalized area under the curve from time zero to infinity (AUC\[0-inf\]/Dose) for each treatment
Conditions Studied
Interventions
- DRUG MTX
Study Locations (1)
Pennsylvania
- Altoona Center for Clinical Research - Duncansville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2012-05 |
| Est. Completion | 2012-08 |
| Phase | Phase 2 |
What the finished NCT01618968 record still lists
NCT01618968 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 265-participant average among 17 other Rheumatoid Arthritis (RA) trials with a reported enrollment target (82% lower).
The record links to 1 condition, with Rheumatoid Arthritis (RA) appearing as the primary indexed condition, and to 1 intervention - of which MTX is the first listed.
NCT01618968 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01618968 about?
NCT01618968 is a clinical study titled "Comparison of Methotrexate (MTX) and the VIBEX™ MTX Device". Relative Bioavailability Comparison study
What is the current status of trial NCT01618968?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 49 participants. The study started on 2012-05. Estimated completion is 2012-08.
What conditions does trial NCT01618968 study?
This clinical trial studies the following conditions: Rheumatoid Arthritis (RA).
What interventions are being tested in trial NCT01618968?
The interventions under investigation include: MTX (DRUG).
Who is sponsoring clinical trial NCT01618968?
This trial is sponsored by Antares Pharma, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01618968 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Rheumatoid Arthritis (RA)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01618968's enrollment target sits among peer trials
49 14th of 17 higher than 4 of 17 other Rheumatoid Arthritis (RA) trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Rheumatoid Arthritis (RA) trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis
RECRUITING · Phase 2
-
Ultrasound Neuroimmune Modulation in Adults With Rheumatoid Arthritis
RECRUITING · Phase 2
-
AlloNK®, an Allogeneic Non-genetically Modified, Cord Blood-derived NK Cell Therapy, in Combination With Rituximab, Studied in Relapsing Forms of B-cell Dependent Rheumatologic Diseases.
RECRUITING · Phase 2
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of ABBV-3373 in Participants With Moderate to Severe Rheumatoid Arthritis (RA)
COMPLETED · Phase 2
-
At-home Ultrasound Localized Therapy for Rheumatoid Arthritis Study [At-home ULTRA Study]
RECRUITING · NA
-
Probiotics in Adults With Rheumatoid Arthritis
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02704858 · 49 participants · Phase 1
Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma
- NCT03516708 · 49 participants · Phase 1
Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer
- NCT03692429 · 49 participants · Phase 1
alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
- NCT04329494 · 49 participants · Phase 1
PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia